StemRIM (TYO:4599)

Japan flag Japan · Delayed Price · Currency is JPY
305.00
-4.00 (-1.29%)
Sep 12, 2025, 3:30 PM JST
-1.29%
Market Cap18.95B
Revenue (ttm)n/a
Net Income (ttm)-1.93B
Shares Out62.14M
EPS (ttm)-31.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume175,600
Average Volume92,575
Open311.00
Previous Close309.00
Day's Range302.00 - 311.00
52-Week Range246.00 - 454.00
Beta0.83
RSI41.73
Earnings DateSep 10, 2025

About StemRIM

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. St... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 44
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4599
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.